Recently, the pharmaceutical companies listed on the Science and Technology Innovation Board have basically revealed the semi-annual report card of 2022, and nearly 80% of Biotech is still in a state of loss, including some companies
that already have innovative drugs on sale.
However, there are also pharmaceutical companies that have achieved year-on-year growth or turned losses into profits
driven by the revenue of listed innovative drugs.
Shanghai Yizhong's 2022 semi-annual report shows that from January to June 2022, the company achieved operating income of 71.
8708 million yuan in the first half of the year, and net profit of 60.
9792 million yuan, a year-on-year turnaround
.
Shanghai Yizhong's self-developed and innovative drug paclitaxel micelle for injection is the company's main source
of revenue.
On October 26, 2021, after paclitaxel micelles were approved for listing, the company carried out commercial production and sales work, and sales increased in the first half of this year, driving revenue growth
.
Paclitaxel is the cornerstone drug of chemotherapy for the treatment of oncological diseases, with a wide range of indications and a rich
clinical use plan.
Paclitaxel polymer micelle for injection is an innovative dosage form of paclitaxel, which is a unique polymer synthesis technology developed by Shanghai Yizhong through a unique polymer synthesis technology, with a very narrow distribution coefficient of pharmaceutical excipients, and the use of nanotechnology to form a unique paclitaxel innovative dosage form
.
Clinical studies on non-small cell lung cancer have shown that the objective response rate (ORR) and progression-free survival (PFS) of paclitaxel micellar tumor treatment have obvious clinical advantages over other taxlitaxel dosage forms that have been listed; In the case of a significant increase in the clinical dose, it has a relatively better safety, does not require any anti-allergic pretreatment before medication, does not need to use a special infusion device, and is convenient for clinical use; Good scientific and technological content and clinical efficacy
.
The product is approved for first-line treatment of non-small cell lung cancer
.
In addition, in clinical practice, it is also applied to the treatment
of other malignant tumors.
It is understood that since the listing of paclitaxel micelles, with the gradual expansion of marketing channels, the demand for products in the market will gradually increase
.
Shanghai Yizhong is accelerating the construction progress of the "annual output of 5 million paclitaxel polymer micelles for injection and supporting facilities" fundraising and investment project to improve production capacity as soon as possible and meet the needs
of future product production and market sales.
Malignant tumors pose a serious threat to human health
.
According to the statistics of the World Health Organization (WHO), the number of new cancer cases worldwide reached 19.
29 million in 2020, of which 4.
57 million new cancers occurred in China, and the number of new cancer onsets is large and the incidence is high
.
With the aging of the population structure, the environmental pollution caused by social development, and the increase of life pressure, malignant tumors will still maintain a high incidence trend worldwide, and will also drive the market of anti-tumor drugs to maintain sustained growth
.
According to the data, in 2015, the market size of anti-tumor drugs in domestic sample hospitals was 20.
690 billion yuan, and by 2020, the scale has grown to 30.
337 billion yuan, with an average annual compound growth rate of 7.
95%.
Chemotherapy is still the cornerstone of malignant tumor treatment, and paclitaxel has unique advantages
in the treatment of lung cancer, breast cancer, stomach cancer, ovarian cancer and other tumors.
In addition to this product, the paclitaxel preparations currently sold on the domestic market include common paclitaxel, paclitaxel liposomes, and albumin paclitaxel
.
Among them, the approved indications for common paclitaxel and paclitaxel liposomes include non-small cell lung cancer
.
The albumin paclitaxel sold in the domestic market is a generic drug, and the indication is only breast cancer
.
